Welcome to our dedicated page for INCYTE SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Incyte Corp. (INCY) filed a Form 144 indicating a proposed sale of 8,617 common shares through Morgan Stanley Smith Barney on or about 03 Jul 2025. The shares have an aggregate market value of $587,272 and represent roughly 0.004% of the 193.57 million shares currently outstanding, signalling a relatively small disposal in percentage terms.
The shares were recently acquired on 02 Jul 2025 via two equity-based awards: 5,935 performance shares and 2,682 restricted shares. The filer reported no other sales in the past three months, and no 10b5-1 plan date was disclosed. The notice includes the standard representation that the seller possesses no undisclosed material adverse information about the company.